Search Results for ""drugs for""
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for "drugs for". Results 2521 to 2530 of 2585 total matches.

Nutritional Supplements for Age-Related Macular Degeneration Revisited

   
The Medical Letter on Drugs and Therapeutics • Jun 24, 2013  (Issue 1419)
The Medical Letter® On Drugs and Therapeutics Volume 55 (Issue 1419) June 24, 2013 Published ...
The results of the Age-Related Eye Disease Study 2 (AREDS2) have now been published. The primary purpose of the study was to evaluate the efficacy and safety of the carotenoids lutein and zeaxanthin and the omega-3 polyunsaturated fatty acids (PUFAs) docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) in reducing the risk of developing advanced age-related macular degeneration (AMD). A secondary goal was to test the effects of reducing the amount of zinc and eliminating beta carotene from the original AREDS formulation. Beta carotene has been shown to increase the risk of...
Med Lett Drugs Ther. 2013 Jun 24;55(1419):50-1 |  Show IntroductionHide Introduction

Belotero Balance for Wrinkles and Folds

   
The Medical Letter on Drugs and Therapeutics • Oct 28, 2013  (Issue 1428)
The Medical Letter® On Drugs and Therapeutics Volume 55 (Issue 1428) October 28, 2013 Published ...
Belotero Balance (Merz), an injectable hyaluronic acid dermal filler, has been approved by the FDA for temporary correction of moderate-to-severe facial wrinkles and folds. Several other hyaluronic acid products are also available for this indication (e.g., Restylane, Perlane, Juvéderm). They have supplanted bovine collagen products, which persist for a shorter time and cause more allergic reactions.
Med Lett Drugs Ther. 2013 Oct 28;55(1428):86-7 |  Show IntroductionHide Introduction

Expanded Table: Antibiotics for Travelers' Diarrhea (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 07, 2019  (Issue 1582)
. www.fdbhealth.com/policies/drug-pricing-policy. 3. Not FDA-approved for treatment of travelers’ diarrhea. 4 ...
View the Expanded Table: Antibiotics for Travelers' Diarrhea
Med Lett Drugs Ther. 2019 Oct 7;61(1582):e160 |  Show IntroductionHide Introduction

In Brief: Phesgo - A Fixed-Dose Combination for HER-2 Positive Breast Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Mar 16, 2021  (Issue 1619)
with permission by First Databank, Inc. All rights reserved. ©2021. www.fdbhealth.com/drug-pricing-policy. 1. AR ...
The FDA has approved a fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase (Phesgo – Genentech) for use in combination with chemotherapy for neoadjuvant (preoperative) treatment of human epidermal growth factor receptor 2 (HER2)-positive, locally advanced, inflammatory, or early-stage breast cancer, or for adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence, or with docetaxel for treatment of those with HER2-positive metastatic breast cancer who have not received anti-HER2 therapy or chemotherapy for metastatic disease....
Med Lett Drugs Ther. 2021 Mar 16;63(1619):e1-2 |  Show IntroductionHide Introduction

Ryzneuta for Prevention of Febrile Neutropenia

   
The Medical Letter on Drugs and Therapeutics • Aug 19, 2024  (Issue 1709)
of chemotherapy-induced febrile neutropenia. Med Lett Drugs Ther 2023; 65:83. 3. J Glaspy et al ...
Efbemalenograstim alfa-vuxw (Ryzneuta – Evive), a nonpegylated granulocyte colony-stimulating factor (G-CSF) conjugated to an Fc fragment of human IgG2, has been approved by the FDA to decrease the incidence of infection, as manifested by febrile neutropenia, in adults with nonmyeloid malignancies receiving myelosuppressive chemotherapy that can cause clinically significant febrile neutropenia. It is the first nonpegylated, long-acting G-CSF to become available in the US. Two pegylated, long-acting G-CSFs, pegfilgrastim (Neulasta, and biosimilars) and eflapegrastim (Rolvedon), are...
Med Lett Drugs Ther. 2024 Aug 19;66(1709):134-5   doi:10.58347/tml.2024.1709d |  Show IntroductionHide Introduction

In Brief: Afamitresgene Autoleucel (Tecelra) for Synovial Sarcoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 14, 2024  (Issue 1713)
. www.fdbhealth.com/ policies/drug-pricing-policy. prolonged severe cytopenias, severe infection, and secondary ...
Afamitresgene autoleucel (Tecelra – Adaptimmune), a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T-cell immunotherapy, has received accelerated approval from the FDA for one-time treatment of adults with unresectable or metastatic synovial sarcoma who received prior chemotherapy and are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen. It is the first gene therapy to be approved in the US for treatment of synovial sarcoma. Accelerated approval of the immunotherapy was based on the...
Med Lett Drugs Ther. 2024 Oct 14;66(1713):e169-70   doi:10.58347/tml.2024.1713i |  Show IntroductionHide Introduction

Measles Revaccination

   
The Medical Letter on Drugs and Therapeutics • Jul 28, 1989  (Issue 797)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
In the first six months of 1989, more than 7,000 cases of measles were reported to the US Centers for Disease Control (CDC), a sharp increase over previous years (Morbid Mortal Weekly Rep, 33:456, July 7, 1989). Many of these cases occurred in children and college students who had previously been vaccinated against the disease. Practitioners have asked, therefore, whether their previously immunized young patients should receive a second (or, in some cases, third) immunization against measles.
Med Lett Drugs Ther. 1989 Jul 28;31(797):69-70 |  Show IntroductionHide Introduction

The Reflotron For Office Chemistry

   
The Medical Letter on Drugs and Therapeutics • Oct 06, 1989  (Issue 802)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
The Reflotron (Boehringer Mannheim), a desk-top colorimetric reflectance analyzer that weighs 12 pounds, can do clinical chemistry tests on 30 l of whole blood, plasma or serum, using multilayered strips containing dry chemicals. A single test takes two to three minutes.
Med Lett Drugs Ther. 1989 Oct 6;31(802):90-1 |  Show IntroductionHide Introduction

Peripheral-Blood Stem-Cells Transplants

   
The Medical Letter on Drugs and Therapeutics • Aug 18, 1995  (Issue 955)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
High-dose chemotherapy, with or without total body radiation, followed by bone marrow transplantation to restore bone marrow function has been used widely in the treatment of malignant diseases in recent years (Medical Letter, 34:79, 1992; 37:25, 1995). Now, however, instead of using bone marrow itself to restore function destroyed by chemotherapy and radiation, many centers infuse hematopoietic stem cells harvested from peripheral blood. Most stem cell transplants have been autologous; allogeneic stem cells have been tried in a small number of patients (WI Bensinger et al, Blood,...
Med Lett Drugs Ther. 1995 Aug 18;37(955):71-2 |  Show IntroductionHide Introduction

Spinal Manipulation

   
The Medical Letter on Drugs and Therapeutics • May 27, 2002  (Issue 1131)
The Medical Letter  On Drugs and Therapeutics www.medicalletter.org Published by The Medical ...
Spinal manipulation has been used to treat not only back and neck pain, but also many other conditions. A recent commentary questioned its safety.
Med Lett Drugs Ther. 2002 May 27;44(1131):50 |  Show IntroductionHide Introduction